Table 1.
9–11 mo | 3–4 y | 7–9 y | 15 y | Total | |
---|---|---|---|---|---|
Baseline characteristics | |||||
Enrolled | 100 | 100 | 100 | 100 | 400 |
Colombo | 37 | 34 | 33 | 33 | 137 |
Badulla | 30 | 32 | 33 | 34 | 129 |
Killinochi | 33 | 34 | 34 | 33 | 134 |
Sex (% female); n/N (%) | |||||
Colombo | 20/37 (54%) | 14/34 (41%) | 13/33 (39%) | 11/33 (33%) | 58/137 (42%) |
Badulla | 11/30 (37%) | 15/32 (47%) | 17/33 (52%) | 15/33 (44%) | 58/129 (45%) |
Killinochi | 12/33 (36%) | 15/34 (44%) | 14/41 (41%) | 14/33 (42%) | 55/134 (41%) |
Fully vaccinated with OPV (%) according to age; n/N (%) | |||||
Colombo | 37/37 (100%) | 34/34 (100%) | 33/33 (100%) | 33/33 (100%) | 137/137 (100%) |
Badulla | 29/30 (97%) | 32/32 (100%) | 33/33 (100%) | 34/34 (100%) | 128/129 (99%) |
Killinochi | 33/33 (100%) | 34/34 (100%) | 34/34 (100%) | 30/33 (91%) | 131/134 (98%) |
Average monthly income per household <$75 (%);n/N (%) | |||||
Colombo | 0/37 (0%) | 0/34 (0%) | 1/33 (3%) | 0/33 (0%) | 1/137 (1%) |
Badulla | 1/30 (3%) | 0/32 (0%) | 3/33 (9%) | 2/34 (6%) | 6/129 (5%) |
Killinochi | 12/33 (36%) | 6/34 (18%) | 0/34 (0%) | 3/33 (9%) | 21/134 (16%) |
Serological results | – | – | – | – | |
Poliovirus Type 1 | |||||
% Positive (95% CI) | 96 (90.1, 98.9) | 99 (94.6, 100) | 99 (94.6, 100) | 97 (91.5, 99.4) | 98 (95.6, 98.9) |
Median titer, (95% CI) | ⩾1448 (⩾1448, ⩾1448) | 724.1 (455, 1152) | 325 (181, 455) | 90.5 (56, 144) | 455 (455, 724) |
Poliovirus Type 2 | |||||
% Positive (95% CI) | 98 (93, 99.8) | 97 (91.5, 99.4) | 99 (94.6, 100) | 100 (96.4, 100) | 99 (96.6, 99.4) |
Median titer, (95% CI) | ⩾1448 (⩾1448, ⩾1448) | 576 (408, 724) | 227 (144, 455) | 113 (90, 181) | 455 (362, 576) |
Poliovirus Type 3 | |||||
% Positive (95% CI) | 95 (88.7, 98.4) | 90 (82.4, 95.1) | 77 (67.5, 84.8) | 75 (65.3, 83.1) | 84 (80.3, 87.7) |
Median titer, (95% CI) | 910 (576, 1152) | 113 (64, 227) | 36 (18, 90) | 28 (11, 45) | 91 (72, 144) |
CI = confidence interval; OPV = oral poliovirus vaccine.